{
    "Trade/Device Name(s)": [
        "Remel Xpect\u00ae Flu A&B",
        "Xpect\u00ae Flu A&B"
    ],
    "Submitter Information": "Remel Inc.",
    "510(k) Number": "K131804",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031565"
    ],
    "Regulatory Class": "1",
    "Product Code(s)": [
        "GNX"
    ],
    "Summary Letter Date": "June 18, 2013",
    "Summary Letter Received Date": "June 19, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3330"
    ],
    "Regulation Name(s)": [
        "Influenza virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology"
    ],
    "Analyte(s)": [
        "Influenza A viral antigen",
        "Influenza B viral antigen"
    ],
    "Specimen Type(s)": [
        "Nasal wash",
        "Nasal swab",
        "Throat swab"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic membrane assay"
    ],
    "Methodologies": [
        "Qualitative antigen detection",
        "Visual read"
    ],
    "Submission Type(s)": [
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Remel Xpect Flu A&B rapid immunochromatographic test for detection of influenza A and B viral antigens.",
    "Indications for Use Summary": "Rapid qualitative detection of influenza A and influenza B viral antigens from nasal wash, nasal swab, and throat swab specimens from symptomatic patients as an aid in the diagnosis of influenza infections; negative results are presumptive and should be confirmed by culture or an FDA-cleared molecular assay.",
    "fda_folder": "Microbiology"
}